Dimebon Antihistamine
Dimebon’s antihistamine properties made this drug popular in Russia starting in 1983. Since that time, many newer, second generation antihistamines have come onto the market and replaced first generation antihistamines such as Dimebon.
Dimebon antihistamine is an H1 – histamine receptor antagonist or blocker. Benadryl (diphenhydramine) is an example of a first generation H1 receptor antagonist antihistamine.
First generation antihistamines, such as Dimebon antihistamine, tend to cross the “blood-brain” barrier and cause side-effects like drowsiness, dry mouth, fatigue, inability to concentrate, etc..
Second generation antihistamines like Allegra (fexofenadine), Claritin (loratadine) and Zyrtec (cetirizine), are much more selective and do not cross the “blood-brain” barrier and therefore do not cause these side-effects.
It is probably due to the fact that the antihistamine drug Dimebon can cross the blood-brain barrier that allows it to have positive effects on those suffering from Alzheimer’s and Huntington’s disease.
Dimebon antihistamine side effects caused it to lose favour in the Russian market. Because of their lower occurrence of side effects second generation antihistamines took over the market in Russian and the antihistamine Dimebon sales declined sharply.
The antihistamine drug Dimebon has gained notoriety lately due to its beneficial effects in the treatment of Alzheimer’s and Huntington’s disease.
Here is a list of first generation antihistamines similar to Dimebon antihistamine:
- Brompheniramine
- Buclizine
- Chlorpheniramine
- Cinnarizine
- Clemastine
- Cyclizine
- Cyproheptadine
- Diphenhydramine
- Diphenylpyraline
- Doxylamine
- Meclozine
- Pheniramine
- Promethazine
- Triprolidine